摘要
表皮生长因子受体(EGFR)基因突变是非小细胞肺癌常见的驱动基因之一。EGFR-酪氨酸激酶抑制剂(TKIs)通过抑制EGFR突变进而发挥抗肿瘤作用。临床研究表明,与传统化疗相比,EGFR-TKIs疗效显著,耐受性好。EGFR-TKIs治疗最常见的不良反应是皮肤毒性和腹泻。本文就EGFR—TKIs相关皮疹的研究进展作一综述。
Epidermal growth factor receptor (EGFR) gene mutation is one of the common driving genes for non-small cell lung cancer .EGFR-tyrosine kinase inhibitors ( TKIs) exert antitumor effects by inhibiting EGFR mutations .Clinical studies have shown that EGFR-TKIs are significantly more effective and well tolerated compared with traditional chemotherapy .The most common side effects of EGFR-TKIs are skin toxicity and diarrhea .This article reviews the research progress of EGFR-TKIs related skin rash .
作者
石新林
杨慧俐
徐兴祥
Shi Xinlin;Yang Huili;Xu Xingziang(Yangzhou University Medical Academy,Yangzhou 225001,China)
出处
《国际呼吸杂志》
2018年第22期1739-1742,共4页
International Journal of Respiration
关键词
表皮生长因子受体-酪氨酸激酶抑制剂
非小细胞肺癌
皮疹
研究进展
Epidermal growth factor receptor-tyrosine kinase inhibitors
Non-small cell lung cancer
Skin rash
Research progress
